S'abonner

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison - 29/04/13

Doi : 10.1016/j.jaci.2013.02.013 
Janine Dretzke, MSc a, , Angela Meadows, MSc a, Nicola Novielli, PhD a, Aarnoud Huissoon, PhD b, Anne Fry-Smith, BA a, Catherine Meads, PhD c
a Department of Public Health, Epidemiology & Biostatistics, University of Birmingham, Birmingham, United Kingdom 
b Department of Immunology, Birmingham Heartlands Hospital, Birmingham, United Kingdom 
c Health Economics Research Group, Brunel University, Uxbridge, United Kingdom 

Corresponding author: Janine Dretzke, MSc, Department of Public Health, Epidemiology & Biostatistics, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.

Abstract

Background

Severe allergic rhinitis uncontrolled by pharmacotherapy can adversely affect quality of life. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have demonstrated effectiveness in this patient group; however, it remains uncertain which route of administration is more effective.

Objectives

We sought to update existing systematic reviews on the clinical effectiveness of SCIT and SLIT versus placebo, to undertake a systematic review of head-to-head trials, and to compare the relative effectiveness of SCIT and SLIT in an adjusted indirect comparison.

Methods

Standard systematic review methods aimed at minimizing bias were used. Double-blind, randomized, placebo-controlled trials of SCIT or SLIT or trials of SCIT versus SLIT were included. Meta-analysis and indirect comparison meta-analysis with meta-regression were performed.

Results

Updated meta-analyses confirmed statistically significant benefits for SCIT and SLIT compared with placebo in adults and, to a lesser extent, in children. Only 1 head-to-head trial met the inclusion criteria; both this and the indirect comparisons did not provide conclusive results in favor of either SCIT or SLIT based on symptom-medication or quality-of-life scores. There was a trend toward favoring SCIT for symptom and medication scores.

Conclusions

Although there is clear evidence of effectiveness of both SCIT and SLIT, superiority of one mode of administration over the other could not be consistently demonstrated through indirect comparison, and further research is needed to establish the comparative effectiveness of SCIT versus SLIT.

Le texte complet de cet article est disponible en PDF.

Key words : Allergic rhinitis, sublingual immunotherapy, subcutaneous immunotherapy, systematic review, meta-analysis, indirect comparison, meta-regression

Abbreviations used : AR, CrI, PRISMA, RCT, SCIT, SLIT, SMD, SSD


Plan


 This work formed part of a wider project commissioned and funded by the UK National Institute for Health Research Health Technology Assessment Programme as project no. 09/78/01.
 Disclosure of potential conflict of interest: J. Dretzke, A. Meadows, N. Novielli, A. Fry-Smith, and C. Meads have received research support from the National Institute for Health Research Health Technology Assessment Programme. A. Huissoon has received consultancy fees from the Meda advisory board, has received lecture fees from and holds stock in GlaxoSmithKline, has received travel support from ALK-Abelló, and ALK-Abelló and Meda Pharmaceuticals have sponsored annual allergy training meetings that his department organizes for primary care physicians.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 5

P. 1361-1366 - mai 2013 Retour au numéro
Article précédent Article précédent
  • Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis
  • Bruce K. Tan, Rakesh K. Chandra, Jonathan Pollak, Atsushi Kato, David B. Conley, Anju T. Peters, Leslie C. Grammer, Pedro C. Avila, Robert C. Kern, Walter F. Stewart, Robert P. Schleimer, Brian S. Schwartz
| Article suivant Article suivant
  • Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity
  • Gertjan J. Driessen, Hanna IJspeert, Corry M.R. Weemaes, Ásgeir Haraldsson, Margreet Trip, Adilia Warris, Michiel van der Flier, Nico Wulffraat, Mijke M.M. Verhagen, Malcolm A. Taylor, Menno C. van Zelm, Jacques J.M. van Dongen, Marcel van Deuren, Mirjam van der Burg

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.